Publications by authors named "Ignacio Tusquets"

Claim this Profile
E
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Roisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, Ignacio Tusquets, Colleen McCormick

Gynecol Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, Antonio Antón, Mauro Mansutti, Ignacio Tusquets

Front Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?
José Alberto Domínguez-Alonso, David Conde-Estévez, David Bosch, Maria Pi-Figueras, Ignacio Tusquets

Clin Transl Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Luca Gianni, Mauro Mansutti, Antonio Anton, Lourdes Calvo, Giancarlo Bisagni, Ignacio Tusquets

JAMA Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
Agustí Barnadas, Luis Manso, Concepción de la Piedra, Cristina Meseguer, Carmen Crespo, Ignacio Tusquets

Bone· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.
Sonia Servitja, Manuel Ramos, Miguel Gil, Pedro Sánchez-Rovira, Sergio Vázquez-Estevez, Ignacio Tusquets

Anticancer Drugs· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors.
Alma Carracedo, Kristof Egervari, Marta Salido, Federico Rojo, Josep M Corominas, Ignacio Tusquets

Breast Cancer Res· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-to-progression in breast cancer: a stratification model for clinical trials.
Juan de la Haba-Rodríguez, Enrique Aranda, Antonio Llombart, Ana Lluch, Emilio Alba, Ignacio Tusquets

Breast· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: a comprehensive analysis.
Cristina Corzo, Beatriz Bellosillo, Josep M Corominas, Marta Salido, Maria Dolors Coll, Ignacio Tusquets

Tumour Biol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pitfalls and caveats in BRCA sequencing.
Beatriz Bellosillo, Ignacio Tusquets

Ultrastruct Pathol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.
Cristina Corzo, Josep M Corominas, Ignacio Tusquets, Marta Salido, Meritxell Bellet

Cancer Genet Cytogenet· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of CHEK2 mutations in Spanish families with hereditary breast cancer.
Beatriz Bellosillo, Ignacio Tusquets, Raquel Longarón, Anna Pérez-Lezaun, Meritxell Bellet

Cancer Genet Cytogenet· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry.
Cristina Corzo, Ignacio Tusquets, Marta Salido, Josep Maria Corominas, Meritxell Bellet

Tumour Biol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral heterogeneity of HER2/neu and topoisomerase IIalpha in breast cancer: a case with clonal monosomy 17.
Cristina Corzo, Ignacio Tusquets, Marta Suarez, Xavier Fabregat, Marta Salido

Cancer Genet Cytogenet· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project].
Miguel Martín, Antonio Llombart-Cussac, Ana Lluch, Emilio Alba, Blanca Munárriz, Ignacio Tusquets

Med Clin (Barc)· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis